DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

ATG-GCSF in New Onset Type 1 Diabetes

Information source: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetes Mellitus, Type 1

Intervention: Anti-Thymocyte Globulin (ATG)/Placebo (Drug); Granulocyte colony stimulating factor (GCSF) (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Official(s) and/or principal investigator(s):
Michael J Haller, M.D., Principal Investigator, Affiliation: University of Florida

Overall contact:
Jay S Skyler, MD, Phone: 305-243-6146, Email: jskyler@miami.edu


This is a three-arm, 1: 1:1 randomized, placebo controlled, double- blinded trial in which at least 28 subjects will receive active Anti-Thymocyte Globulin and Granulocyte colony-stimulating factor (ATG-GCSF), at least 28 subjects will receive ATG alone and at least 28 subjects will receive placebo alone within 100 days from diagnosis of Type 1 Diabetes (T1D). The primary objective of the study will be to determine the safety and ability of low dose ATG plus GCSF and low dose ATG alone to retain/enhance C-peptide production in new onset T1D patients demonstrating residual beta cell function.

Clinical Details

Official title: Antithymocyte Globulin (ATG) and Pegylated Granulocyte Colony Stimulating Factor (GCSF) in New Onset Type 1 Diabetes

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Primary outcome: Measure of area under the stimulated C-peptide curve over the first 2 hours of a mixed meal glucose tolerance test conducted at the one-year visit.

Detailed description: The primary statistical hypothesis to be assessed in the study is whether the 2 hour area under the curve (change in baseline to 12 months) in residual beta cell function (C-peptide) will differ between those treated with ATG and GCSF or ATG alone as compared with placebo. The study will also examine the effect of the proposed treatments on surrogate markers for immunologic and metabolic outcomes.


Minimum age: 12 Years. Maximum age: 45 Years. Gender(s): Both.


Inclusion Criteria:

- Must be > 12 years < 46

- Must have a diagnosis of T1D for less than 100 days at randomization

- Willing to provide Informed Consent or have a parent or legal guardian

provide informed consent if the subject is <18 years of age

- Positive for at least one islet cell autoantibody; glutamic acid decarboxylase 65

(GAD65A), Insulin micro IAA (mIAA), if obtained within 10 days of the onset of insulin therapy, islet antigen 2 (IA-2A), Islet Cell Antigen (ICA), or zinc transporter 8 (ZnT8A)

- Must have stimulated C-peptide levels = 0. 2 pmol/ml measured during a mixed meal

tolerance test (MMTT) conducted at least 21 days from diagnosis of diabetes and within one month (37 days) of randomization

- Must be Epstein-Barr virus (EBV PCR) negative within two weeks of randomization if

EBV seronegative at screening

- Be at least 6 weeks from last live immunization

- Participants are required to receive killed influenza vaccination at least 2 weeks

prior to randomization when vaccine for the current or upcoming flu season is available

- Be willing to forgo vaccines during the treatment period and for 3 months following

last dose of study drug

- Be willing to comply with intensive diabetes management

Exclusion Criteria:

- Be immunodeficient or have clinically significant chronic lymphopenia: (Leukopenia

(< 3,000 leukocytes /µL), neutropenia (<1,500 neutrophils/µL), lymphopenia (<800 lymphocytes/µL), or thrombocytopenia (<100,000 platelets/µL).

- Have active signs or symptoms of acute infection at the time of randomization

- Have evidence of prior or current tuberculosis infection as assessed by purified

protein derivative (PPD), interferon gamma release assay (IGRA) or by history

- Be currently pregnant or lactating, or anticipate getting pregnant within the two

year study period

- Require use of other immunosuppressive agents including chronic use of systemic


- Have evidence of current or past human immunodeficiency virus (HIV), Hepatitis B or

Hepatitis C infection

- Have any complicating medical issues or abnormal clinical laboratory results that may

interfere with study conduct, or cause increased risk to include pre-existing cardiac disease, chronic obstructive pulmonary disease (COPD), sickle cell disease, neurological, or blood count abnormalities

- Have a history of malignancies other than skin

- Evidence of liver dysfunction with aspartate aminotransferase (AST) or alanine

transaminase (ALT) greater than 3 times the upper limits of normal

- Evidence of renal dysfunction with creatinine greater than 1. 5 times the upper limit

of normal

- Vaccination with a live virus within the last 6 weeks

- Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control

within prior 7 days of screening

- Active participation in another T1D treatment study in the previous 30 days

- Prior treatment with abatacept or anti-cd3

- Known allergy to GCSF or ATG

- Prior treatment with ATG or known allergy to rabbit derived products

- Any condition that in the investigator's opinion may adversely affect study

participation or may compromise the study results

Locations and Contacts

Jay S Skyler, MD, Phone: 305-243-6146, Email: jskyler@miami.edu

Yale University, New Haven, Connecticut 06519, United States; Recruiting
Laurie Feldman, Phone: 203-737-2760, Email: laurie.feldman@yale.edu
Kevan Herold, MD, Principal Investigator

University of Florida, Gainesville, Florida 32610, United States; Recruiting
Miriam Cintron, Phone: 352-273-5580, Email: cintrm@peds.ufl.edu
Jessica Ferguson, Phone: 352-294-5761, Email: jaycee@peds.ufl.edu
Michael Haller, MD, Principal Investigator

University of Miami, Miami, Florida 33136, United States; Recruiting
Della Matheson, Phone: 305-243-3781, Email: dmatheso@med.miami.edu
Lisa Rafkin, Phone: (305) 243-6146, Email: Lrafkin@miami.edu
Jennifer Marks, MD, Principal Investigator

Indiana University-Riley Hospital for Children, Indianapolis, Indiana 46202, United States; Recruiting
Vanessa Patrick, Phone: 317-274-2579, Email: vpatrick@iu.edu
Linda DiMeglio, MD, Principal Investigator

University of Minnesota, Minneapolis, Minnesota 55455, United States; Recruiting
Carrie Gibson, Phone: 612-624-5958, Email: gibso002@umn.edu
Chris Kwong, Phone: 612-624-2922, Email: kwong001@umn.edu
Toni Moran, MD, Principal Investigator

Vanderbilt Eskind Diabetes Clinic, Nashville, Tennessee 37232, United States; Recruiting
Anne Brown, Phone: 615-343-5968, Email: anne.brown@vanderbilt.edu
Faith Brendle, Phone: 615-936-8638, Email: faith.brendle@vanderbilt.edu
William Russell, MD, Principal Investigator

Benaroya Research Institute, Seattle, Washington 98101, United States; Recruiting
Marli McCulloch-Olson, Phone: 206-515-5239, Email: Marli@benaroyaresearch.org
Carla Greenbaum, MD, Principal Investigator

Additional Information

Type 1 Diabetes TrialNet

Starting date: December 2014
Last updated: February 24, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017